Sensibilidad y especificidad del índice de salud prostática (PHI), para el escrutinio de cáncer prostático, evitando la práctica de biopsias innecesarias
DOI:
https://doi.org/10.48193/y3k71796Palabras clave:
Cancer de prostataResumen
No en carta al editor
Referencias
Stephan C, Bangma C, Vignati G, Bartsch G, Lein M, Jung K, et al. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. The International Journal of Biological Markers. 2009;24(2): 65–69. https://doi.org/10.5301/jbm.2009.1349.
Garrido MM, Marta JC, Ribeiro RM, Pinheiro LC, Holdenrieder S, Guimarães JT. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations. In Vivo (Athens, Greece). 2021;35(6): 3431–3439. https://doi.org/10.21873/invivo.12643.
Deng L, Yue D, Wang X, Li H. Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen. Translational Andrology and Urology. 2023;12(2): 261–270. https://doi.org/10.21037/tau-23-29.
Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. The Journal of Urology. 2023;210(1): 46–53. https://doi.org/10.1097/JU.0000000000003491.
Agnello L, Vidali M, Giglio RV, Gambino CM, Ciaccio AM, Lo Sasso B, et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine. 2022;60(8): 1261–1277. https://doi.org/10.1515/cclm-2022-0354.
Coronel-Carvajal C. Los objetivos de la investigación. Revista Archivo Médico de Camagüey. 2023;27.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Revista Mexicana de Urología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
